Join the Epilepsy group to help and get support from people like you.
Epilepsy News (Page 3)
Study IDs Reference Levels for Serum Neurofilament Light Chain in Youth
TUESDAY, Aug. 8, 2023 – Measures of serum neurofilament light chain (sNfL) clinically differentiate children with neurological conditions versus healthy children, according to a study published...
FDA Approves Zonisade (zonisamide oral suspension) for the Treatment of Partial-Onset Seizures
The first and only FDA-approved zonisamide oral liquid formulation WOBURN, Mass., July 18, 2022 /PRNewswire/ – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing...
FDA Approves Ztalmy (ganaxolone) for Seizures Associated with CDKL5 Deficiency Disorder
RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today...
FDA Approves Eprontia (topiramate) Oral Solution for Epilepsy and Preventive Treatment of Migraine
WOBURN, MA, November 8, 2021 – Azurity Pharmaceuticals, Inc. a private specialty pharmaceutical company focused on developing innovative products to meet the unique needs of patients with underserved ...
Vimpat (lacosamide) Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric Use for People Living with Epilepsy
ATLANTA, Nov. 17, 2020 /PRNewswire/ – UCB, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Vimpat (lacosamide) CV as adjunctive therapy...
FDA Approves Valtoco (diazepam nasal spray) as a Seizure Rescue Treatment
SAN DIEGO, CA – January 13, 2020 – Neurelis, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Valtoco (diazepam nasal spray) as an acute treatment of intermittent, s...
FDA Approves Sympazan (clobazam) Oral Film for Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome
WARREN, N.J., Nov. 2, 2018 /PRNewswire/ – Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved...
FDA Approves Diacomit (stiripentol) for Seizures Associated with Dravet Syndrome
On August 20, 2018, the U.S. Food and Drug Administration (FDA) approved Diacomit (stiripentol) for seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam. ...
FDA Approves Epidiolex (cannabidiol) to Treat Lennox-Gastaut Syndrome and Dravet Syndrome
June 25, 2018 – The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy,...
UCB Announces Briviact (brivaracetam) Now Approved by FDA to Treat Partial-Onset (Focal) Seizures in Pediatric Epilepsy Patients
Atlanta, Georgia (U.S.) & Brussels (Belgium), 0700 CEST, 14 May, 2018: UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for...
Sunovion’s Aptiom (eslicarbazepine acetate) Receives FDA Approval for Expanded Indication to Treat Partial-Onset Seizures in Children and Adolescents 4 Years of Age and Older
MARLBOROUGH, Mass.--(BUSINESS WIRE)--September 14, 2017 Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug...
FDA Approves New indication for Briviact (brivaracetam) as Monotherapy Treatment of Partial-Onset Seizures in Adults
Atlanta, Georgia (U.S.) & Brussels (Belgium), 15 September, 2017 – 0700 (CEST): UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (...
FDA Approves Carnexiv (carbamazepine) injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types
DEERFIELD, Ill.--(BUSINESS WIRE) October 07, 2016 --Lundbeck announced today that the U.S. Food and Drug Administration (FDA) has approved Carnexiv (carbamazepine) injection as a short-term...
FDA Medwatch Alert: Lamotrigine Orally Disintegrating Tablet 200 mg by Impax: Recall - Incorrect Labeling of Blister Cards
ISSUE: Impax Laboratories, Inc. issued a voluntary nationwide retail level recall on August 19, 2016 for one lot of Lamotrigine Orally Disintegrating Tablet (ODT) 200 mg, NDC 0115-1529-08, Lot #...
Eisai Announces FDA Approval of Fycompa (perampanel) Oral Suspension
WOODCLIFF LAKE, N.J., May 2, 2016 /PRNewswire/ – Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Fycompa (perampanel) CIII Oral Suspension as adjunctive...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Seizures, Lennox-Gastaut Syndrome
Related drug support groups
gabapentin, Klonopin, clonazepam, Lyrica, Lamictal, lorazepam, diazepam, Topamax, lamotrigine, view more... pregabalin, Depakote, Neurontin, topiramate, Keppra, Trileptal, Tegretol, oxcarbazepine, phenobarbital, levetiracetam, Vimpat